- |||||||||| Jakafi oral (ruxolitinib) / Novartis, Incyte, azacitidine / Generic mfg.
Clinical, Review, Journal: New Concepts of Treatment for Patients with Myelofibrosis. (Pubmed Central) - Mar 26, 2020
Pacritinib, a non-myelosuppressive JAK2-selective inhibitor, is currently in a dose-ranging study mandated by regulatory authorities...Emerging data supports the addition of azacitidine to ruxolitinib in some patients...This is important, because cytopenias are the commonest reason for ruxolitinib interruption and/or dose reduction, and dose optimization of ruxolitinib is tied to its survival benefit. The activin receptor ligand trap, sotatercept, and the anti-fibrotic agent, PRM-151, have shown promise in this regard.
- |||||||||| zinpentraxin alfa (RG6354) / Roche
Trial completion date: A Phase 2 Study of RO7490677 In Participants With Myelofibrosis (clinicaltrials.gov) - Nov 19, 2019
P2, N=98, Active, not recruiting,
The activin receptor ligand trap, sotatercept, and the anti-fibrotic agent, PRM-151, have shown promise in this regard. Trial completion date: Apr 2019 --> Jan 2020
- |||||||||| recombinant human serum amyloid P subconjunctival (PRM 151) / BMS
Clinical, Journal: Resting-State Functional Connectivity Is Associated With Cerebrospinal Fluid Levels of the Synaptic Protein NPTX2 in Non-demented Older Adults. (Pubmed Central) - Jun 25, 2019
...This study examined whether Neuronal Pentraxin 2 (NPTX2), a synaptic protein that mediates homeostatic strengthening of inhibitory circuits to control cortical excitability, is associated with functional connectivity as measured by resting-state functional magnetic resonance imaging (rsfMRI) in five large-scale cognitive brain networks...Findings also confirmed prior reports that individuals with MCI have lower levels of NPTX2 compared to those with normal cognition. Taken together, the results suggest that NPTX2 mechanisms may play a central role among older individuals in connectivity within the salience/ventral attention network and for cognitive tasks that require modulation of attention and response selection.
- |||||||||| recombinant human serum amyloid P subconjunctival (PRM 151) / BMS, Ofev (nintedanib) / Boehringer Ingelheim, Esbriet (pirfenidone) / Shionogi
Journal: Diagnosis and Treatment of Interstitial Lung Diseases (Pubmed Central) - Apr 30, 2019
the serum protein pentraxin 2, antibodies against the growth factor CTGF). On the other hand, the efficacy of the registered antifibrotic medicaments, nintedanib and pirfenidone, in interstitial lung diseases other than idiopathic pulmonary fibrosis is being evaluated.
- |||||||||| recombinant human pentraxin-2 (PRM 151) / Roche
Biomarker, Journal: Declining levels of functionally specialized synaptic proteins in plasma neuronal exosomes with progression of Alzheimer's disease. (Pubmed Central) - Oct 25, 2018
In a preclinical period, 6-11 yr before the onset of dementia, the NDE levels of all but NPTX2 were significantly lower than those of matched controls, and levels of all proteins declined significantly with the development of dementia. Reductions in NDE levels of these specialized excitatory synaptic proteins may therefore be indicative of the extent of cognitive loss and may reflect progression of the severity of AD.-Goetzl, E. J., Abner, E. L., Jicha, G. A., Kapogiannis, D., Schwartz, J. B. Declining levels of functionally specialized synaptic proteins in plasma neuronal exosomes with progression of Alzheimer's disease.
- |||||||||| zinpentraxin alfa (RG6354) / Roche
Phase classification: PRM151F-12GL: A Phase 1b Study of IV PRM151 in Patients With Idiopathic Pulmonary Fibrosis (IPF) (clinicaltrials.gov) - Oct 10, 2018
P1b, N=21, Completed,
Reductions in NDE levels of these specialized excitatory synaptic proteins may therefore be indicative of the extent of cognitive loss and may reflect progression of the severity of AD.-Goetzl, E. J., Abner, E. L., Jicha, G. A., Kapogiannis, D., Schwartz, J. B. Declining levels of functionally specialized synaptic proteins in plasma neuronal exosomes with progression of Alzheimer's disease. Phase classification: P1 --> P1b
- |||||||||| Review, Journal: Developmental Therapeutics in Myeloproliferative Neoplasms. (Pubmed Central) - Apr 24, 2018
In polycythemia vera, a novel interferon administered every 2 weeks is being developed for front-line therapy in high-risk individuals, and inhibitors of human double minute 2 (HDM2) have shown promise in preclinical studies, as have HDAC inhibitors such as givinostat (both in the laboratory and in the clinic). Ruxolitinib is approved for second-line therapy of polycythemia vera and is being developed for essential thrombocythemia.
- |||||||||| recombinant human pentraxin-2 (PRM 151) / Roche
Journal: Role of neoplastic monocyte-derived fibrocytes in primary myelofibrosis. (Pubmed Central) - Aug 13, 2017
Treatment of the xenograft mice with the fibrocyte inhibitor serum amyloid P (SAP; pentraxin-2) significantly prolonged survival and slowed the development of BM fibrosis. Collectively, our data suggest that neoplastic fibrocytes contribute to the induction of BM fibrosis in PMF, and inhibiting fibrocyte differentiation with SAP may interfere with this process.
- |||||||||| zinpentraxin alfa (RG6354) / Roche
Enrollment closed: A Phase 2 Study of RO7490677 In Participants With Myelofibrosis (clinicaltrials.gov) - Dec 8, 2016
P2, N=98, Active, not recruiting,
Collectively, our data suggest that neoplastic fibrocytes contribute to the induction of BM fibrosis in PMF, and inhibiting fibrocyte differentiation with SAP may interfere with this process. Recruiting --> Active, not recruiting
|
